Inside the 2026 LSPedia Logistics Forum

FDA 483s jumped tenfold in 2025, the first DSCSA warning letter to a dispenser went to a medical spa, and the small dispenser deadline moved without changing anything else. What came out of the 2026 LSPedia Logistics Forum.

Key takeaways box

• DSCSA 483s jumped 10x in 2025. Of 16 publicly known DSCSA 483s issued between July 2018 and March 2026, eleven landed in 2025 alone.

• The first warning letter to a dispenser went to a medical spa in April 2026, for transacting outside authorized trading partners and holding product with no product identifier.

• The small dispenser deadline moved to November 27, 2027, and nothing else changed. Only serialization shifted. Every other obligation applies today.

For three days in August, manufacturers, wholesalers, 3PLs, health systems and pharmacies came to Birmingham, Michigan for the second annual LSPedia Logistics Forum. CEO Riya Cao set the framing on the first morning: this is not a trade show, it is a room of stakeholders working out how to collaborate. Here is what came out of it.

‍‍

Enforcement has teeth now

The keynote came from Abha Kundi, Counsel at ArentFox Schiff, who brings roughly fifteen years of FDA experience including a team lead role in the Center for Drug Evaluation and Research (CDER) Office of Compliance.

The numbers make the shift concrete. Sixteen DSCSA 483s appear in publicly available FDA enforcement documents between July 2018 and March 2026, and the distribution is the story: one in 2018, none for three years, one in 2022, none in 2023, one in 2024, then eleven in 2025 and two more in the first quarter of 2026. Twelve went to manufacturers, three to wholesale distributors, one to a dispenser.

Four DSCSA warning letters have been issued. Three went to wholesale distributors between 2019 and 2025, for failures that read as a checklist of the obligations people assume are handled: responding to illegitimate product notifications, quarantining suspect product, keeping six-year records, buying only from authorized trading partners, holding state licensure, and answering a regulator’s TI/TS request within one business day.

The fourth changes the picture downstream. In April 2026, the FDA issued its first DSCSA warning letter to a dispenser, and the dispenser was a medical spa. It was cited for transacting outside authorized trading partners, evidenced by a gap between units of a botulinum neurotoxin product purchased and units administered, and for an unlabeled vial found onsite. If your mental model of a DSCSA dispenser is a pharmacy, that letter is worth sitting with.

‍

The small dispenser date moved. Nothing else did.

Two weeks before the Forum, FDA extended the small dispenser deadline to November 27, 2027, automatically and with no filing, for dispensers whose owning company has 25 or fewer full-time licensed pharmacists or qualified technicians. Serialization shifted. Every other DSCSA obligation still applies today.

One live deadline is attached: the mandated feasibility survey closes September 22, 2026. What it asks and how long it takes → FDA's DSCSA Small Dispensers Assessment

‍

What pharmacies are actually missing

The most candid hour came from Erin Parsons, Senior Director of Operations & Compliance at LSPedia, with Rony Foumia, Director of Pharmacy Services at Children’s Hospital of Michigan.

Foumia’s advice was to ask staff, not leadership, four questions: what is DSCSA, what is your receiving process, what do you do if you doubt a drug’s legitimacy, and where is your quarantine area. In his account, those are undefined in roughly nine out of ten pharmacies he walks into. Board inspectors ask the same questions, and they ask a staff pharmacist.

Two lines carried the session: If you didn’t document it, it didn’t happen and How can you say that you’re operating at the highest level to protect your community?

Parsons framed where pharmacies struggle as people, process and technology, in that order. The reframing worth carrying: success is not measured by sending EPCIS, but by whether a pharmacist can safely receive medication without interrupting patient care.

‍

Compliance data is financial data

The revenue session was the one people came for. The premise: serialized movement data is a financial control instrument and almost nobody uses it as one. The barrier is not technical. The data sits in Quality and the value sits in Finance.

The sharpest example came from the finance seat. Chargeback data frequently does not carry the lot number, so chargebacks cannot be reconciled against actual product movement, and returns and duplicate discounts tangle on top of that. Without the lot, there is no trace. Add a recall and it gets worse.

The 340B session made the same case from a different angle: product moves but the data does not, because some covered entities manage 340B shipments without sending the required EPCIS messages. The prescribed loop was detect, diagnose, engage, resolve, monitor. And the line that echoed the dispenser session almost word for word: if we did not record it, it did not happen.

‍

NDC 12: a 2033 deadline that is a 2027 problem

The closing panel brought together Ullrich Mayeski of GS1, Bruce Harold of KeySource, and LSPedia’s John Monsour and Ilir Ivezaj. Monsour framed the difference from DSCSA: that was phased, and NDC 12 is everybody at once. Mayeski made the point most people miss, that the rule has two parts and the second one, dropping the linear barcode requirement, is where manufacturers are actually starting. Harold’s advice was the most repeated of the session: do your inventory, because the NDC is in more places than you think.

The rule, the dates and the preparation steps in full → NDC 12: the FDA’s 12-digit NDC rule

‍

Six more things the room agreed on

• Audit readiness is navigation, not data. Michael Rowe described a table of contents for everything you do to comply, the thing that shows a regulator in five minutes that you know your own process. The item missed most often is the escalation path.

• Exceptions are a small share of transactions and the largest share of time. This is why GS1’s exceptions handling addendum became one of its most downloaded documents.

• You will not resolve every exception, and that is fine. What matters is having an SOP, following it, and documenting that you did. One unresolved exception with a complete paper trail is defensible. The same exception with nothing behind it is not.

• Master data failures are usually self-inflicted. Repackaging or relabeling without control of your own master data produces records that work in your system and nowhere else.

• AI is earning its place in narrow lanes. Regulatory and recall intelligence, predictive risk analysis, agent-driven decision support and audit analytics. One organization cut purchasing review from three or four hours a day to about thirty minutes by managing exceptions instead of transactions.

• Nobody gets to interoperability alone. Compliance protects patients, operational excellence protects pharmacy teams, and collaboration protects the supply chain.

‍

Thank you

To everyone who cleared two days to be in the room, and also to our Logistics Forum sponsors, Amista and MatchRx.

‍

Save the date: Logistics Forum 2027

The tentative date and location for the third annual LSPedia Logistics Forum is August 1, 2027 at the Townsend Hotel. Watch our socials for updates and additional details.